| CASE REPORT |
|
| Year : 2022 | Volume
: 2
| Issue : 2 | Page : 500-502 |
|
|
A case of multifocal uveal metastases from T790M-mutated non-small-cell lung carcinoma with an unexpected reaction to Osimertinib
Ding-Liang Xu, Yue-Yang Zhu, Xin-Zhe Wu, Jing Huang, Wen-Song Zhang
Department of Ophthalmology, The Second Hospital of Jilin University, Changchun, Jilin Province, China
Correspondence Address:
Wen-Song Zhang
Department of Ophthalmology, The Second Hospital of Jilin University, Yatai Street, Changchun - 130 000, Jilin Province
China
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/ijo.IJO_2061_21
|
|
|
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used in the treatment of metastatic non-small-cell lung carcinoma (NSCLC) patients with targetable EGFR-T790M mutations. We describe the case of a 61-year-old Chinese female confirmed with multifocal uveal metastases from T790M-mutated NSCLC after developing acquired resistance to icotinib (a first-generation EGFR-TKI). Therefore, she was instituted on oral osimertinib. The uveal masses were reported to completely disappear on anterior segment examination, ultrasound biomicroscopy (UBM), and ocular color doppler flow imaging (CDFI) after 41 weeks. However, the patient got worse and eventually died from systemic metastases 4 months later.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
